Who founded Scynexis?

Scynexis was founded by Yves J. Ribeill.

Who are Scynexis's investors?

Scynexis's investors include Decheng Capital, Foresite Capital, Deerfield Management Company, RA Capital.

How much funding has Scynexis raised?

Scynexis has disclosed $5.7M raised across 1 round.

Where is Scynexis headquartered?

Scynexis is headquartered in Durham, US.

Scynexis

NASDAQ: SCYX

Durham, US · 4 known investors

Find your way into Scynexis

59 people in our graph share verified history with the Scynexis team — schools, employers, funds. One of them is your warm intro.

Anta Ndiayeunlockedknows Yves J. Ribeill · together at BPI France (overlapped)

×10knows the team · via BPI France

knows the team · via Argobiostudio

SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.

Biotech

Founders & leadership

Yves J. Ribeill inFounder, Chief Executive Officer & President2000–2015Yves Ribeill is founder and former CEO of SCYNEXIS, which he led from inception through IPO, and previously spent a decade at Rhône-Poulenc and Aventis contributing to the development of multiple FDA-approved therapies. He currently serves as CEO of Enodia Therapeutics and Partner & Entrepreneur in Residence at Argobio Studio.

Charles F. Osborne, Jr.Executive

Brian SchwabinExecutive

David Angulo inChief Executive OfficerDavid Angulo is an infectious disease specialist with over 20 years of drug development experience across infectious diseases and dermatology in large, medium, and biotechnology companies. He has held leadership roles managing clinical research, regulatory affairs, and product development teams across multiple therapeutic areas.

Board

Laurent ArthaudBoard director

Mounia ChaouiBoard director

Jean-Yves NothiasBoard director

Ed PenhoetBoard director

Ann F. HanhamBoard director

Horace D. NalleBoard director

Pamela J. KirbyBoard director

Patrick LangloisBoard director

Investors · 4

Decheng CapitalMenlo Park

Foresite CapitalWest Hollywood

Deerfield Management CompanyreportedNew York

RA CapitalreportedBoston

Reported raises · per SEC filings

Form D private placements

$5.7M disclosed across 1 round · 2011

▶$5.7MraisedFeb 2012 · 11 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Yves J. RibeillExecutive Officer, Director
Horace D. NalleDirector
Pamela J. KirbyDirector
Laurent ArthaudDirector
Mounia ChaouiDirector
Patrick LangloisDirector
Jean-Yves NothiasDirector
Charles F. Osborne, Jr.Executive Officer
Brian SchwabExecutive Officer
Ed PenhoetDirector
Ann F. HanhamDirector

Offering amount: $15M
Amount sold: $5.7M
First sale: Dec 2011
Incorporated: Corporation, Delaware
Federal exemptions: 06

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events

$101.5Mvaluation at IPOApr 2015 · $7.70/share · 424B4

filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2015	$224K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2014	$224.3K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infectionsfinance.yahoo.com · Nov 2025

Frequently asked questions

What does Scynexis do?: SCYNEXIS develops fungerp-based antifungal therapies, including SCY-247, for treating and preventing severe, progressive, and often fatal fungal diseases and antimicrobial-resistant infections. The company focuses on rare diseases affecting underserved patient populations.
Who founded Scynexis?: Scynexis was founded by Yves J. Ribeill.
Who are Scynexis's investors?: Scynexis's investors include Decheng Capital, Foresite Capital, Deerfield Management Company, RA Capital.
How much funding has Scynexis raised?: Scynexis has disclosed $5.7M raised across 1 round.
Where is Scynexis headquartered?: Scynexis is headquartered in Durham, US.